ArticleCancer immunology, immunotherapy : CII2025
Immunotyping of thyroid cancer for clinical outcomes and implications.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Inhibitory receptor states, immune homeostasis and the benefit-risk boundary of cancer checkpoint blockade.Frontiers in immunology · 2026Review
- Constructing a chemokine-based model and identifyingTranslational cancer research · 2025Article
- Personalised immunotherapy strategies informed by single cell profiling in thyroid cancer: a mini review.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTumor immune microenvironment (TIME) plays a crucial role in cancer development. However, the prognostic significance of immune-related genes (IRGs) in thyroid cancer (THCA) is unclear.
methodsThe Cancer Genome Atlas (TCGA)-THCA dataset was downloaded. The CIBERSORT algorithm was used to determine immune cell infiltration and a Weighted Gene Co-expression Network Analysis (WGCNA) was executed to obtain immune cell-related genes. Univariate Cox analysis was performed to screen prognostic genes and THCA samples were categorized into different immune cell-related clusters. The correlations between clusters and THCA prognosis and clinical characteristics were explored. Differentially expressed genes (DEGs) between THCA and controls from TCGA-THCA were identified. Macrophage and lymphocyte abundances, IFN-γ, wound healing, and TGF-beta levels were determined using the single set gene set enrichment analysis (GSEA), and THCA samples were categorized into different immune-related clusters, and corresponding genes were obtained from WGCNA. DEGs, IRGs, and immune-related clusters genes were subjected to overlap analysis to obtain differentially expressed IRGs (DE-IRGs), and these were subjected to least absolute shrinkage and selection operator (LASSO) and multivariate Cox analyses to identify prognosis-related genes. THCA samples were divided into high/low-risk groups based on the median risk score. Furthermore, the prognostic model's utility in predicting immunotherapy response was analyzed. The potential therapeutic drugs were obtained. The expression of the corresponding genes in 10 pairs of clinical specimens was evaluated and those of proteins were analyzed by immunofluorescence assay.
resultsTCGA-THCA samples were categorized into two immune cell-related clusters based on 141 prognostic immune cell-related genes. Significant differences in survival and clinical characteristics such as T Stage between clusters. In total, 16,648 DEGs between THCA and control samples were extracted. THCA samples were categorized into two immune-related clusters and were found to affect the prognosis and TIME of THCA. By using LASSO and multivariate Cox analyses for 88 DE-IRGs, three prognostic IRGs, namely FLNC, IL18, and MMP17 were identified. The TIDE score of the low-risk group was significantly lower than that of the other one, indicating that these samples were more responsive to immunotherapy. The 50% inhibitory concentration (IC50) of camptothecin, methotrexate, rapamycin, and others were notably different between the risk groups.
conclusionBased on bioinformatics analysis, we constructed an immune-related prognosis model for THCA, which is expected to provide new ideas for studies related to the prognosis and treatment of THCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.